Guided Therapeutics Inc (GTHP) stock
Close on Oct 19, 2026Market cap $15.45MP/E –Yield –
Guided Therapeutics Inc grew revenue 450.8% to $650.00K over the twelve months to Jun 30, 2026. Free cash flow was -$1.07M. At the latest close the market valued the company at $15.45M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $15.45M
- P/E ratio
- –
- Price to sales
- 23.76
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -6.93%
Fundamentals
- Revenue
- $650.00K
- Net income
- -$3.07M
- EPS, diluted
- -$0.04
- Free cash flow
- -$1.07M
- Book value per share
- -$0.06
- Diluted shares
- 97M
Trading
- Previous close
- $0.19
- Open
- $0.18
- Day's range
- $0.15 – $0.18
- Volume
- 310,783
- Average volume (20 days)
- 82,149
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | GTHP | S&P 500 | Difference | GTHP per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -30.4% | +0.6% | −31.1 pts | ||
| 3 months | -42.9% | +3.4% | −46.2 pts | ||
| Year to date | -70.4% | +13.3% | −83.6 pts | ||
| 1 year | -30.5% | +16.6% | −47.1 pts | ||
| 3 years | +6.7% | +86.4% | −79.7 pts | +2.2% | +23.1% |
| 5 years | -71.3% | +81.9% | −153.1 pts | -22.1% | +12.7% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Guided Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
About Guided Therapeutics
Electromedical & Electrotherapeutic Apparatus
Guided Therapeutics, Inc. is a medical technology company focused on developing and commercializing medical devices for cancer detection. Its primary product is the LuViva Advanced Cervical Scan, a non-invasive, biophotonic point-of-care device designed to identify cervical cancers and precancers using light scanning, alongside single-use disposable calibration and alignment cervical guides. The company's technology serves two main applications: primary cervical cancer screening in developing regions and triage following abnormal Pap or HPV tests in developed markets. LuViva targets healthcare programs, foreign governments, non-governmental organizations, and clinical OB-GYN practices.
Company profile, executives and historyGuided Therapeutics stock: common questions
What is Guided Therapeutics's stock price?
GTHP closed at $0.16 on Oct 19, 2026, down 15.79% on the day.
What is Guided Therapeutics's market cap?
Guided Therapeutics was worth $15.45M at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
What is GTHP's P/E ratio?
Guided Therapeutics lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.04), so it has no meaningful P/E ratio.
How much revenue does Guided Therapeutics make?
Guided Therapeutics reported revenue of $650.00K for the twelve months to Jun 30, 2026, up 450.8% from a year earlier.
Does Guided Therapeutics pay a dividend?
No. Guided Therapeutics has not paid a cash dividend over the last twelve months.
How has GTHP stock performed over the past year?
Including dividends, GTHP returned -30.5% over the past year, against +16.6% for the S&P 500.
Who are Guided Therapeutics's competitors?
Companies most similar to Guided Therapeutics by business, industry and size include POSC, ITOC, FEMY, CODX, PLSE.
See a number that looks wrong?